Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CCNT1 | O60563 | 12/20 | 0.39 |
| ▸ | CDK4 | P11802 | 12/20 | 0.39 |
| ▸ | CCND1 | P24385 | 12/20 | 0.39 |
| ▸ | CDK9 | P50750 | 12/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 5/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | PI4KA | P42356 | 1/20 | 0.37 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.37 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.37 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21540519 | 0.82 | SMN1; SMN2 (0.58) | SMN1; SMN2L3MBTL1CDK2ADORA2AADORA2B | |
| SCHEMBL20600683 | 0.81 | SMN1; SMN2 (0.46) | SMN1; SMN2CCNT1CDK4CCND1CDK9 | |
| SCHEMBL26515108 | 0.81 | SMN1; SMN2 (0.50) | SMN1; SMN2CCNT1CDK4CCND1CDK9 | |
| SCHEMBL27296365 | 0.81 | SMN1; SMN2 (0.53) | SMN1; SMN2L3MBTL1CDK2ADORA2AADORA2B | |
| SCHEMBL26515088 | 0.79 | SMN1; SMN2 (0.44) | SMN1; SMN2CCNT1CDK4CCND1CDK9 | |
| SCHEMBL10147308 | 0.77 | LMNA (0.40) | SMN1; SMN2L3MBTL1DHODHADORA2AADORA1 | |
| SCHEMBL16938822 | 0.76 | HCAR3 (0.43) | SMN1; SMN2CCNT1CDK4CCND1CDK9 | |
| SCHEMBL24922833 | 0.75 | DHODH (0.38) | DHODH | |
| SCHEMBL22598705 | 0.74 | SMN1; SMN2 (0.41) | SMN1; SMN2L3MBTL1CDK2DHODHADORA2A | |
| SCHEMBL23068067 | 0.72 | CCNT1 (0.52) | SMN1; SMN2CCNT1CDK4CCND1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240240182-A1 | HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2024-07-18 | — | — | US | disclosed |
| US-20240209339-A1 | REDIRECTING RISC FOR RNA EDITING | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240209374-A1 | iRNA COMPOSITIONS AND METHODS FOR SILENCING CHITINASE 3-LIKE PROTEIN 1/YKL-40 (CHI3L1/YKL-40) PROTEIN | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240209373-A1 | ELONGATION OF VERY LONG CHAIN FATTY ACIDS PROTEIN 1 (ELOVL1) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240209373-A1 | ELONGATION OF VERY LONG CHAIN FATTY ACIDS PROTEIN 1 (ELOVL1) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-12018260-B2 | Tunable Reversir™ compounds | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240067972-A1 | DIPEPTIDYL PEPTIDASE 4 (DPP4) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2024-02-29 | — | — | US | disclosed |
| US-20240067972-A1 | DIPEPTIDYL PEPTIDASE 4 (DPP4) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2024-02-29 | — | — | US | disclosed |
| US-20230287424-A1 | RNAi COMPOSITIONS AND METHODS OF USE THEREOF FOR DELIVERY BY INHALATION | BANK OF AMERICA, N.A. | 2023-09-14 | — | — | US | disclosed |
| US-20230272382-A1 | COMPLEMENT COMPONENT C3 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING COMPLEMENT COMPONENT C3-ASSOCIATED DISEASES | BANK OF AMERICA, N.A. | 2023-08-31 | — | — | US | disclosed |
| US-20220127615-A1 | CORONAVIRUS IRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2022-04-28 | — | — | US | disclosed |
| US-20220127604-A1 | REVERSIR TM COMPOUNDS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-04-28 | — | — | US | disclosed |
| US-20220002724-A1 | AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-01-06 | — | — | US | disclosed |
| US-10995336-B2 | Serpina1 iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-05-04 | — | — | US | disclosed |
| US-20190316127-A1 | SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2019-10-17 | — | — | US | disclosed |
| US-10233448-B2 | Modified double-stranded RNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-20180208927-A1 | MULTI-TARGETED SINGLE ENTITY CONJUGATES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-07-26 | — | — | US | disclosed |
| US-20170369872-A1 | REVERSIR TM COMPOUNDS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-12-28 | — | — | US | disclosed |
| US-20170275626-A1 | MODIFIED DOUBLE-STRANDED RNA AGENTS | BANK OF AMERICA, N.A. | 2017-09-28 | — | — | US | disclosed |
| US-20170275626-A1 | MODIFIED DOUBLE-STRANDED RNA AGENTS | BANK OF AMERICA, N.A. | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287424-A1 | RNAi COMPOSITIONS AND METHODS OF USE THEREOF FOR DELIVERY BY INHALATION | MTREX, RNASEH1, RNASE1 | SMN1; SMN2 877/4885CCNT1 4743/4885CDK4 4877/4885 |
| US-20240067972-A1 | DIPEPTIDYL PEPTIDASE 4 (DPP4) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | DPP4, DPP3, DPP7 | SMN1; SMN2 2997/4885CCNT1 4850/4885CDK4 3112/4885 |
| US-12018260-B2 | Tunable Reversir™ compounds | SNRPE, PLK1, LDLR | SMN1; SMN2 1252/4885CCNT1 2211/4885CDK4 1576/4885 |
| US-20240209339-A1 | REDIRECTING RISC FOR RNA EDITING | ADAR, AGO2, METTL16 | SMN1; SMN2 1463/4885CCNT1 4024/4885CDK4 4405/4885 |
| US-20240209374-A1 | iRNA COMPOSITIONS AND METHODS FOR SILENCING CHITINASE 3-LIKE PROTEIN 1/YKL-40 (CHI3L1/YKL-40) PROTEIN | CHI3L1, CHIA, CHI3L2 | SMN1; SMN2 3073/4885CCNT1 4835/4885CDK4 4843/4885 |
| US-20220002724-A1 | AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENT COMPOSITIONS AND METHODS OF USE THEREOF | APP, APBA1, PSEN1 | SMN1; SMN2 613/4885CCNT1 4427/4885CDK4 4619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.